Drug intelligence / Profile preview

bivalent SARS-CoV-2 conjugate vaccine

Development stage: Preclinical
Lead developer: Inventprise
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Inventprise's bivalent SARS-CoV-2 conjugate vaccine is a clinical-stage vaccine designed to provide broad and durable protection against evolving COVID-19 variants. It utilizes protein-protein conjugation technology, linking SARS-CoV-2 Beta and Delta strain spike proteins to a detoxified diphtheria-derived carrier protein (rCRM197) and incorporating Toll-Like Receptor (TLR) agonist adjuvants. This approach aims to stimulate both humoral (antibody-mediated) and cellular (T-cell) immunity, offering a potentially longer-lasting immune response compared to some mRNA vaccines. Preclinical study results, published in April 2025, demonstrated its ability to elicit robust immune responses.

Targets

SARS-CoV-2 spikeTLR9 (Toll-like receptor 9)

Beyond the preview

Go deeper on bivalent SARS-CoV-2 conjugate vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bivalent SARS-CoV-2 conjugate vaccine.